Anti-CALHM6 monoclonal antibody

Pre-made anti-CALHM6 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to CALHM6/CALHM6 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP0822-Ab-1/ GM-Tg-hg-IP0822-Ab-2Anti-Human CALHM6 monoclonal antibodyHuman
GM-Tg-rg-IP0822-Ab-1/ GM-Tg-rg-IP0822-Ab-2Anti-Rat CALHM6 monoclonal antibodyRat
GM-Tg-mg-IP0822-Ab-1/ GM-Tg-mg-IP0822-Ab-2Anti-Mouse CALHM6 monoclonal antibodyMouse
GM-Tg-cynog-IP0822-Ab-1/ GM-Tg-cynog-IP0822-Ab-2Anti-Cynomolgus/ Rhesus macaque CALHM6 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP0822-Ab-1/ GM-Tg-felg-IP0822-Ab-2Anti-Feline CALHM6 monoclonal antibodyFeline
GM-Tg-cang-IP0822-Ab-1/ GM-Tg-cang-IP0822-Ab-2Anti-Canine CALHM6 monoclonal antibodyCanine
GM-Tg-bovg-IP0822-Ab-1/ GM-Tg-bovg-IP0822-Ab-2Anti-Bovine CALHM6 monoclonal antibodyBovine
GM-Tg-equg-IP0822-Ab-1/ GM-Tg-equg-IP0822-Ab-2Anti-Equine CALHM6 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP0822-Ab-1/ GM-Tg-hg-IP0822-Ab-2; GM-Tg-rg-IP0822-Ab-1/ GM-Tg-rg-IP0822-Ab-2;
GM-Tg-mg-IP0822-Ab-1/ GM-Tg-mg-IP0822-Ab-2; GM-Tg-cynog-IP0822-Ab-1/ GM-Tg-cynog-IP0822-Ab-2;
GM-Tg-felg-IP0822-Ab-1/ GM-Tg-felg-IP0822-Ab-2; GM-Tg-cang-IP0822-Ab-1/ GM-Tg-cang-IP0822-Ab-2;
GM-Tg-bovg-IP0822-Ab-1/ GM-Tg-bovg-IP0822-Ab-2; GM-Tg-equg-IP0822-Ab-1/ GM-Tg-equg-IP0822-Ab-2
Products NameAnti-CALHM6 monoclonal antibody
Formatmab
Target NameCALHM6
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-CALHM6 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP0822-Ag-1Recombinant multi-species CAHM6/ CALHM6/ C6orf187 protein


    Target information

    Target IDGM-IP0822
    Target NameCALHM6
    Gene ID441168,215900,294430,715967,612530,101095901,616136
    Gene Symbol and SynonymsA630077B13Rik,C6orf187,CALHM6,dJ93H18.5,FAM26F,INAM,RGD1304835
    Uniprot AccessionQ5R3K3,Q561R8
    Uniprot Entry NameCAHM6_HUMAN,CAHM6_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000188820
    Target ClassificationIon Channel

    The target: CALHM6, gene name: CALHM6, also named as C6orf187, FAM26F, INAM, dJ93H18.5. Predicted to enable cation channel activity. Predicted to be involved in cation transmembrane transport. Predicted to be integral component of membrane. Predicted to be integral component of plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.